Braun Stacey Associates Inc. Invests $11.80 Million in Crinetics Pharmaceuticals, Inc. $CRNX

Posted by Brenda Bartman on Jun 28th, 2026

Braun Stacey Associates Inc. bought a new stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 324,808 shares of the company’s stock, valued at approximately $11,797,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Wellington Management Group LLP boosted its stake in Crinetics Pharmaceuticals by 44.3% during the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company’s stock worth $349,110,000 after purchasing an additional 2,574,683 shares during the period. Baker BROS. Advisors LP increased its stake in Crinetics Pharmaceuticals by 488.9% in the fourth quarter. Baker BROS. Advisors LP now owns 1,648,869 shares of the company’s stock valued at $76,755,000 after purchasing an additional 1,368,869 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Crinetics Pharmaceuticals by 20.2% in the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company’s stock valued at $322,736,000 after buying an additional 1,163,000 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Crinetics Pharmaceuticals by 279.2% during the third quarter. JPMorgan Chase & Co. now owns 1,258,722 shares of the company’s stock worth $52,426,000 after buying an additional 926,765 shares during the period. Finally, GW&K Investment Management LLC boosted its stake in shares of Crinetics Pharmaceuticals by 73.6% during the fourth quarter. GW&K Investment Management LLC now owns 1,476,325 shares of the company’s stock worth $68,723,000 after buying an additional 625,779 shares during the period. Hedge funds and other institutional investors own 98.51% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on CRNX. Weiss Ratings restated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Monday, April 20th. Citizens Jmp reaffirmed a “market outperform” rating and set a $95.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, June 15th. Wall Street Zen raised Crinetics Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Oppenheimer cut their price target on Crinetics Pharmaceuticals from $87.00 to $84.00 and set an “outperform” rating for the company in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Crinetics Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $76.12.

Read Our Latest Research Report on CRNX

Crinetics Pharmaceuticals Stock Up 4.9%

Shares of NASDAQ:CRNX opened at $36.70 on Friday. The company has a market cap of $3.87 billion, a price-to-earnings ratio of -7.15 and a beta of 0.24. The firm’s 50-day simple moving average is $36.71 and its 200-day simple moving average is $41.93. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $25.83 and a fifty-two week high of $57.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.01). The firm had revenue of $10.73 million for the quarter, compared to analysts’ expectations of $8.51 million. Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company’s revenue for the quarter was up 2873.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.04) earnings per share. On average, research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -4.86 EPS for the current year.

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Jeff E. Knight sold 85,163 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total value of $3,415,036.30. Following the completion of the sale, the insider directly owned 105,289 shares of the company’s stock, valued at $4,222,088.90. This trade represents a 44.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stephanie Okey sold 6,900 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $35.67, for a total value of $246,123.00. Following the completion of the sale, the director owned 6,400 shares in the company, valued at approximately $228,288. This trade represents a 51.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company’s stock.

Crinetics Pharmaceuticals Profile

(Free Report)

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.